LGD-4033

Purity: >98% I Molecular Formula: C14H12F6N20 Molecular Weight: 338.25/mol I Sequence: Non-Peptide

DESCRIPTION:

Selective Androgen Receptor Modulators (SARMs) provide the benefits of traditional anabolic/androgenic agents such as testosterone (including increased muscle mass, fat loss, and bone density), while having lower unwanted side effects characteristic of oral anabolics (aromatization / increased DHT). By stimulating the androgen receptor, SARMs can provide a similar therapeutic outcome to androgen therapy without any increase in androgen levels. SARMs have the potential to take the place of androgens, and therefore exert many of the same positive effects on muscle tissue. SARMs can be administered in an injectable dosage form and are absorbed orally are with no liver toxicity as with most oral steroids. The anabolic effect has been measured to be roughly the same or greater than testosterone. It has also been shown to produce dose-dependent increases in bone mineral density and mechanical strength, decrease body fat and increase lean body mass. LGD-4033 is a relatively new SARM on the market. It can be dosed orally at low doses and has a very strong anabolic effect.

PROTOCOL:

Content & Potency: 500mcg capsule provided in a quantity of 30 capsules
Suggested dosage: Take one capsule once daily for 30 days in cycle (one month on, one month off)

CLINICAL RESEARCH:

The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Me

LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups.
Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone —
binding globulin, high density lipoprotein cholesterol, and triglyceride levels. Follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean bodymass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation. LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.

Basaria, Shehzad & Collins, Lauren & Dillon, Edgar & Orwoll, Katie & Storer, Thomas & Miciek, Renee & Ulloor, Jagadish & Zhang, Anqi & Eder, Richard & Zientek, Heather & Gordon, Gilad & Kazmi, Syed & Sheffield-Moore, Melinda & Bhasin, Shalender. (2012). The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. The journals of gerontology. Series A, Biological sciences and medical sciences. 68.